MTNB — Matinas BioPharma Holdings Share News
0.000.00%
Last trade - 00:00Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors
Brief: Matinas Biopharma Announces Agreement For The Acquisition Of Preferred Stock And Appointment Of Dr. Robin L. Smith To The Board Of Directors
Brief: Matinas Biopharma Appoints Evelyn D’An To Board Of Directors As Audit Committee Chair
Brief: Matinas BioPharma Receives NYSE Noncompliance Notice
Brief: Matinas Biopharma Announces The Termination Of Mat2203 Partnership Negotiations And Implements Immediate Workforce Reduction
Brief: Matinas BioPharma Q2 Net Income USD -5.719 Million
Brief: Matinas Biopharma Reports Successful Treatment Of Patient With Limb-Threatening Mucor Infection In Its Oral Mat2203 Compassionate/Expanded Use Access Program
Brief: Matinas BioPharma Q1 Net Income USD -5.824 Million
Brief: Matinas BioPharma Announces Positive In vivo Safety Data With Its Oral LNC-Docetaxel Formulation
Brief: Matinas Biopharma Provides Positive Outcomes Update On The MAT2203 Compassionate/Expanded Use Access Program
Brief: Matinas Biopharma- Non-Inferiority Trial Will Enroll About 216 Patients With Primary Endpoint Of All-Cause Mortality
Brief: Matinas Biopharma Provides Update To Mat2203 Regulatory And Development Pathway after Feedback From FDA